antibody form
purified antibody
clone
7, monoclonal
form
lyophilized
species reactivity
human
isotype
IgG1
General description
Plasminogen activator inhibitor 1 (PAI-1) is a secreted glycoprotein of approximately 50 kDa, which functions as the primary regulator of uPA and tPA activity. PAI-1 and the related inhibitor, PAI-2, are members of the serine proteinase inhibitor (serpin) gene superfamily. PAI-1 is produced by a variety of cell types and is present in normal human plasma. It exists as two conformationally distinct forms, latent and active. The active form binds to uPA in a 1:1 complex resulting in the inhibition of proteolytic activity. Active PAI-1 rapidly converts to the latent form but can be stabilized in the active conformation by binding to the cell adhesion glycoprotein, vitronectin. Latent PAI-1 can be activated in vitro by exposure to denaturants such as SDS or guanidine. PAI-1 levels are increased in a number of disease states including coronary artery disease, venous thrombosis, obesity and various types of cancer. Recent studies indicate that elevated PAI-1 may be a useful prognostic marker for several types of cancers, particularly breast and lung.
Purified mouse monoclonal antibody. Recognizes the latent form of the ~50 kDa PAI-1 protein.
Recognizes the latent form of the ~50 kDa PAI-1 protein in conditioned media from dexamethasone-treated HT-1080 cells. Sold under license of U.S. Patent 5,422,245.
This Anti-PAI-1 Mouse mAb (7) is validated for use in Immunoblotting, Immunoprecipitation for the detection of PAI-1.
Immunogen
partially purified human PAI-1 from conditioned medium of dexamethasone-treated HT1080 cells
Application
Immunoblotting (1 μg/ml)
Immunoprecipitation (see applications refrences)
Immunoprecipitation (see applications refrences)
Physical form
Lyophilized from a volatile buffer, 100 μg BSA.
Preparation Note
We recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Lyophilized antibodies shou
Analysis Note
Positive Control
Conditioned media from dexamethasone-treated HT-1080 cells
Conditioned media from dexamethasone-treated HT-1080 cells
Other Notes
PAI (Ab-3) will detect latent but not active PAI-1. Antibody should be titrated for optimal results in individual systems.
Legal Information
Sold under license of U.S. Patent 5,422,245.
法规信息
新产品
此项目有
J Keijer et al.
Blood, 78(2), 401-409 (1991-07-15)
Plasminogen activator inhibitor 1 (PAI-1), an essential regulatory protein of the fibrinolytic system, harbors interaction sites for plasminogen activators (tissue-type [t-PA] and urokinase-type [u-PA]) and for fibrin. In this study, anti-PAI-1 monoclonal antibodies (MoAbs) were used to identify interaction sites
F Blasi et al.
Seminars in cancer biology, 1(2), 117-126 (1990-04-01)
Plasmin formation is an important and complex process in vivo. It involves two enzymes, two inhibitors, the substrate and specific receptors. Plasmin formation, dependent on the urokinase-type plasminogen activator (uPA), is discussed in its biochemical, regulatory and physiological aspects and
D A Lawrence et al.
The Journal of biological chemistry, 269(21), 15223-15228 (1994-05-27)
Plasminogen activator inhibitor type 1 (PAI-1) is the rapid physiologic inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA). In plasma and the extracellular matrix, PAI-1 is associated with the adhesive glycoprotein vitronectin. In order to characterize the PAI-1
P J Declerck et al.
Thrombosis research. Supplement, 10, 3-9 (1990-01-01)
Four monoclonal antibodies, MA-7D4, MA-7F5, MA-12A4 and MA-15H12, were raised against human plasminogen activator inhibitor-1 (PAI-1). MA-7D4 and MA-7F5 had an inhibitory effect on PAI-1 activity, whereas MA-15H12 and MA-12A4 did not affect PAI-1 activity. MA-7D4 was used previously as
H Pedersen et al.
Cancer research, 54(1), 120-123 (1994-01-01)
The urokinase pathway of plasminogen activation is involved in proteolytic degradation of various tissues, including dissolution of the extracellular matrix and basement membranes during the process of cancer cell invasion. We have studied the prognostic value of urokinase-type plasminogen activator
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持